Retatrutide — the first triple-agonist peptide hitting GLP-1, GIP, and glucagon receptors — delivered 71.2 lbs average weight loss in Phase 3. Here’s what the research actually shows and what researchers need to know about sourcing Reta GLP-3R for laboratory use in 2026.
Let me tell you something most people miss about peptide research. The molecules that end up mattering the most are
Deep dive into GLP-1 peptide research: how GLP-1 receptor agonists work, key research variants including semaglutide, tirzepatide, and retatrutide, and current research directions.
Comprehensive TB-500 research guide covering dosage protocols, mechanism of action, half-life, reconstitution, and comparison with BPC-157 for research purposes.
Complete semaglutide research guide: STEP-1 dosage escalation, mechanism of extended half-life, comparison with tirzepatide and retatrutide, and sourcing standards.
Research guide for tirzepatide peptide covering Phase 3 dosage escalation protocol, reconstitution instructions, mechanism of action, and third-party COA sourcing standards.
Comprehensive BPC-157 research guide covering mechanisms of action, dosage parameters from preclinical models, acetate vs standard form, and combination protocols with TB-500.
A complete researcher’s guide to MK-677 (ibutamoren), covering its mechanism as a ghrelin receptor agonist, preclinical and clinical dosage parameters, research applications in muscle wasting and bone density, and quality standards.
A comprehensive researcher’s guide to GHK-Cu (glycyl-L-histidyl-L-lysine copper), covering mechanisms of action, preclinical dosage parameters, reconstitution, storage, and research applications in skin regeneration and tissue repair.
A peptide bond is the amide linkage created when the carboxyl group of one alpha-amino acid reacts with the amino
